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Abstract
The measurement of early bactericidal activity (EBA) is the first step in the clinical investigation of antituberculosis agents. EBA is deter-
mined by quantifying the viable sputum mycobacterial load on consecutive days of treatment. To investigate whether time to positivity
(TTP) in mycobacterial liquid culture can substitute for colony forming unit (CFU) counting on agar plates we compared the error varia-
tion of TTP and CFU in 2115 pooled sputum samples collected overnight from 250 individuals included in five EBA studies. We found
that the technical variation between duplicate laboratory measurements and the within-subject or day-to-day variation were similar for
TTP (8.5% and 27.4% of total variation, respectively) and CFU (6.7% and 29.3% of total variation). The ability of the measurements to
separate the EBA of 22 treatment arms was determined with group rank correlation of means and one-way analysis of variance. Except
for the EBA over 0–2 days, individual and group EBAs measured with TTP and CFU were highly correlated. Treatment group means
rank correlation coefficients were r = 0.472, r = 0.910 and r = 0.818, respectively, for EBA 0–2 days, EBA 0–7 days and EBA 0–14 days.
Analysis of variance significantly favoured TTP over CFU for discrimination between groups with F values of 6.58 and 1.87, 7.77 and
4.58, and 8.71 and 3.56, respectively. We conclude that TTP is an acceptable alternative to CFU counting for the determination of the
viable sputum mycobacterial load in EBA studies of up to 14 days duration.
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Background
In 1980 Jindani et al. [1] published details of an assessment of
the early bactericidal activity (EBA) of antituberculosis agents
by measurement of the decline in viable colony forming units
(CFU) of Mycobacterium tuberculosis in sputum of patients
with sputum-microscopy smear-positive pulmonary tubercu-
losis. Nearly all available antituberculosis agents were stud-
ied, either alone or in combination, over the first 14 days of
therapy. A considerable amount of valuable information was
generated by this study, which contributed to a better
understanding of the actions of antituberculosis agents during
early therapy. The determination of EBA is established as a
first step in the clinical evaluation of a new antituberculosis
agent. Involving a relatively small number of patients with
smear-positive pulmonary tuberculosis, these studies confirm
that the new agent is actually killing mycobacteria in sputum,
enable the evaluation of its efficacy in relation to dosage and
pharmacokinetics, and offer the opportunity for an early
evaluation of toxicity.
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Throughout the first 10–15 years of the exploration of
EBA the quantification of M. tuberculosis in sputum depended
on culture of sputum specimens on solid media and counting
of viable CFU of M. tuberculosis at various dilutions expressed
as logCFU [2]. While this methodology has proven its value
over three decades, it is labour intensive and requires spe-
cialized laboratory facilities, and there is a relatively long lag
before results become available. With the accelerating avail-
ability of new antituberculosis agents there is a need for a
methodology that could also be used in less sophisticated
communities where tuberculosis patients can be more read-
ily recruited for appropriate studies, and that might measure
the bactericidal activity of an agent in the same manner as
sputum viable CFU counting.
An attractive alternative to enumeration of CFU for the
quantification of M. tuberculosis is culture in liquid media and
determination of the time to positivity (TTP), reflecting the
detection of critical metabolic activity. Studies have demon-
strated that liquid media are more sensitive than solid media
for culture of mycobacteria from sputum and that TTP at
diagnosis correlates with disease severity and treatment out-
come in pulmonary tuberculosis patients [3–10]. To examine
whether logCFU and TTP lead to the same conclusion, we
examined the respective ability of both measurements to dis-
criminate between 22 treatment arms in five recent EBA
studies.
Methods and Materials
Sputum samples from five consecutive EBA studies were sub-
mitted to the MRC Centre for Molecular and Cellular Biol-
ogy at the Faculty of Health Sciences, Stellenbosch
University, Cape Town, between 2005 and 2010. The centre
has abundant experience in EBA studies [2,11–16] and
recruits patients from urban areas where the incidence of
tuberculosis is estimated to exceed 1000/100 000 cases per
year [17]. Consenting adults with smear-positive pulmonary
TB were randomized to different daily drug dosage with
experimental or positive control antituberculosis agents over
7 to 14 days. Sputum was collected overnight at regular
intervals to monitor the fall of the viable bacterial load. The
relevant ethical and regulatory bodies approved each study
and every participant gave written informed consent. The
results of three studies have been published to date
[11,12,16].
Patients and sputum samples
Two hundred and fifty patients were recruited into 22 treat-
ment arms with either experimental compounds (TMC207,
OPC-67683, PA-824) or control regimens (H, R or HRZE).
Median group size was 12 subjects (mean, 11.4; range, 6–
16). Sputum was sampled at baseline before drug treatment
and daily or every 2 days thereafter. Two baseline sputa
were collected in three studies. In one study logCFU and
TTP were measured only at baseline and at day 7. Duration
of drug treatment was either 7 days (two studies) or
14 days (three studies). A total of 2371 samples were sub-
mitted, of which 2115 (89.2%) were available for this analy-
sis. Due to various technical issues, such as lack of growth
and contamination, no TTP was available from 141 sputa
(5.9%) and no logCFU from 173 sputa (7.3%). There was no
significant difference between the mean TTP and mean log-
CFU of samples with and without matched measurements
(data not shown).
Sputum samples and processing
All sputum samples were submitted to the same laboratory
for analysis using consistent protocols for collection, trans-
port and processing during the whole study period. Speci-
mens were homogenized by magnetic stirring for 30 min. A
maximum volume of 10 mL of sample was added to an equal
volume of 0.1% dithiothreitol (Sputasol; Oxoid, Cambridge,
UK), mixed well and left for 20 min to obtain digested spu-
tum for further processing.
For CFU determination, two series of five ten-fold dilu-
tions (1 · 10)1, 1 · 10)2, 1 · 10)3, 1 · 10)4 and 1 · 10)5)
of digested sputum were prepared in sterile Tween/saline.
Selective Middlebrook 7H11 agar, enriched with Middlebrook
OADC (Becton Dickinson, Johannesburg, South Africa), was
prepared by adding Selectatab (Mast; Bootle, Merseyside,
UK) containing polymixin B sulphate (200 units/mL), ampho-
tericin B (10 mg/L), carbenicillin (50 mg/L) and trimethoprim
(20 mg/L) and poured into two-compartment 90-mm Petri
dishes. A volume of 0.1 mL of each dilution, including the
neat sample, was inoculated in quadruplicate onto the selec-
tive agar. The agar plates were incubated for 3 weeks at
37C without supplemental CO2 and CFU counted at that
dilution, where 20–200 CFU were visible for counting.
Counts were averaged and corrected for dilution factors to
result in a CFU count per ml sputum.
For culture in BACTEC MGIT 960, 5 mL digested sputum
was mixed with an equal volume of 2% NaOH (Mycoprep;
Becton Dickinson) in a 50-mL centrifuge tube and decontam-
inated for 15 min at room temperature. The mixture was
neutralized by addition of M/15 sterile phosphate buffer (pH
6.8) up to the 45 mL mark. This mixture was centrifuged for
15 min at 3000 g. The supernatant was discarded and the
pellet resuspended in M/15 sterile phosphate buffer (pH 6.8)
to give a final volume of 2 mL. Two MGIT tubes were pre-
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pared by adding OADC enrichment and PANTA (Becton
Dickinson) containing polymyxin B (6000 units), trimetho-
prim (600 lg), amphotericin B (600 lg), azlocillin (600 lg)
and nalidixic acid (2400 lg), and 0.5 mL of the resuspended
pellet inoculated into each tube. The tubes were incubated
at 37C in the BACTEC MGIT 960 system, which automati-
cally flags positive cultures. TTP was averaged and recorded
in hours.
Statistics
We analysed the data in three steps. First, individual TTP
and logCFU measurements were examined for overall corre-
lation and total variation. Total variation was further exam-
ined for the proportions of purely technical variation and
within-subject variation. Technical variation as the proportion
due to purely technical factors could be estimated from
duplicate measurements of the same specimens in the labo-
ratory. Within-subject variation, a component of which is the
technical variation, can also be described as the random
biological or day-to-day variation. This component was esti-
mated from consecutive baseline samples from the same
subject and also indirectly from individual residuals in regres-
sion of logCFU and TTP on time in days. Within-subject
variation, when compared to between-subject variation,
essentially determines the precision of individual EBA mea-
surements.
Second, we calculated the EBAs for each subject with log-
CFU and TTP and examined the correlation for the periods
0–2, 0–7 and 0–14 days. For the purpose of this study, EBA
was defined by the fall in logCFU or by prolongation of TTP
in hours. The efficacy of treatment is judged by the daily
change in measurements in sputum from Day x to Day y:
• For logCFU:
EBA(logCFU) = [logCFU(Day x))logCFU(Day y)]/[y)x]
• For TTP:
EBA(TTP) = [TTP(Day y))TTP(Day x)]/[y)x]
Third, mean EBA(TTP) and mean EBA(logCFU) values were
calculated for the treatment groups. The ability of EBA(TTP)
and EBA(logCFU) to discriminate between groups was exam-
ined in two ways: (i) by mean group EBA rank correlation,
and (ii) by comparison of between-treatment variation rela-
tive to within-treatment variation using one-way analysis of
variance (ANOVA).
Pearson or Spearman rank correlations were employed
where appropriate. Linear regression was performed with
the method of least squares. Error variation is expressed as
mean ± standard deviation (SD), or as F statistic when
ANOVA is used. Higher F values represent higher between-
group variation relative to within-group variation and hence
better discrimination between groups. p values of <0.05
were accepted as significant. All calculations and graphics
were created with ‘R’ software (http://www.R-project.org).
Results
Individual measurements
A correlation plot of all individual TTP and logCFU pairs
shows crowding of points and visually moderate correlation
(Fig. 1a). The scatter away from the general trend is largely
due to error variation in logCFU and in TTP. The total varia-
tion expressed as overall SD for TTP and logCFU is 50.44
and 1.088, respectively. In accordance with the ten-fold dilu-
tion technique employed for CFU counting we grouped log-
FIG. 1. Correlation of individual logCFU and TTP. (a) 2198 matched
pairs of logCFU and TTP with a linear correlation coefficient of
r = )0.72. There is considerable scatter, which is due to error varia-
tion of the measurements (SD for TTP, 50.44; for logCFU, 1.088).
(b) Plot of mean TTP against mean logCFU values calculated by
grouping logCFU in ranges <3, 3–4, 4–5, 5–6, 6–7, >7 and obtaining
the means of logCFU and TTP of values corresponding to these log-
CFU ranges. The colour coding indicates different studies.
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CFU in ranges <3, 3–4, 4–5, 5–6, 6–7, >7 (Fig. 1b). The cor-
relation is clearly monotonic with a linear correlation coeffi-
cient of r = )0.72, but there is also a clear trend towards
non-linearity in the range beyond 5 logCFU, hinting at an
inherent threshold in the liquid culture system preventing a
further decrease of TTP at higher logCFU levels.
The technical component of the SD for TTP was esti-
mated as 4.287 from the differences between duplicate val-
ues used to create single TTP values. Single logCFU values
were created by averaging from quadruplicates. In order to
obtain a reasonably fair comparison of technical error we
first created duplicates by taking the average of the two
counts from the first agar bi-plate as the first duplicate and
the average of the two counts from the second agar bi-plate
as the second duplicate. The estimated technical SD from
such duplicates was 0.0728. In relation to the variation
between observations shown in Fig. 1, the mean technical
SDs compared with the overall SDs give ratios of 4.287/
50.44 = 0.085 for TTP and 0.0728/1.088 = 0.067 for logCFU.
Proportions of 8.5% and 6.7% of the total SDs are small and
of a similar order of magnitude, indicating that there is little
to choose between TTP and logCFU with respect to the
influence of technical error variation.
Within-subject variation of logCFU and TTP, a component
of which is the technical variation, essentially determines the
precision of individual EBA assessments. Measurements made
on two successive days before the start of treatment were
used to estimate within-subject (day-to-day) error variation
directly from the differences between successive days
(Table 1, studies 1–3). Within-subject variation was also esti-
mated indirectly from residuals in regression of logCFU and
TTP on time (days) for individual subjects. In order to include
a similar number of different measurements such regressions
were fitted on three studies from day 2 to the last day of
study (Table 1, examples 4–6). In relation to the variation
between observations shown in Fig. 1, the mean day-to-day
error SDs compared with the overall SDs give ratios of
13.81/50.44 = 0.274 for TTP and 0.319/1.088 = 0.293 for log-
CFU. These proportions of 27.4% and 29.3% of the total SD
are very close to each other, indicating, again, that there is
nothing to choose between logCFU and TTP with respect to
within-subject variation or technical error variation.
Individual subject EBAs
Correlations between individual EBAs at days 0–2, 0–7 and
0–14 were all significant (p <0.0001) and improved from
moderate to strong with increasing study duration (r =
0.468, r = 0.649 and r = 0.741, respectively). For EBA day
0–7, day 7 values were extrapolated where only day 6 and
8 were available, which resulted in the highest number of
individual EBAs of the durations investigated (Fig. 2).
While the correlation of individual values, the error varia-
tion analysis and the individual EBA correlation give no indi-
cation that TTP is inferior to logCFU, the real test is how
well TTP and logCFU discriminate between treatment arms.
There are two issues: whether they assign the same ranks to
treatments, and whether between-treatment variation rela-
tive to within-treatment variation is similar with the two
measures.
Treatment group EBAs
Fig. 3 illustrates EBA(TTP) and EBA(logCFU) curves of 22
groups. Mean EBA(TTP) and mean EBA(logCFU) values were
strongly correlated for all three periods measured (Table 2).
It should be noted, however, that Pearson means correla-
tions are strongly influenced by treatments that have much
greater EBA values than the other treatments. This is partic-
ularly important for EBA day 0–2, for which the Spearman
rank correlation coefficient is only 0.472, which, while still
statistically significant (p 0.036), is much smaller than for
EBA day 0–7 and EBA day 0–14.
Fig. 4 illustrates treatment means, ranks and separation
between treatment means by displaying two-dimensional
TABLE 1. Within-subject variation of logCFU and TTP
Successive drug-free days logCFU, SD TTP, SD
Example 1 0.400 13.34
Example 2 0.208 10.54
Example 3 0.288 7.58
Periods with drug treatment
Example 4 (days 2–14) 0.444 19.13
Example 5 (days 2–14) 0.252 12.18
Example 6 (days 2–7) 0.323 20.08
Overall mean error variation, SD 0.319 13.81
FIG. 2. Correlation of individual EBAs. This figure shows 224 indi-
vidual EBA values for day 0–7 plotted against each other. EBA(log-
CFU) and EBA(TTP) are highly correlated with r = 0.649, p <0.0001.
The colour coding indicates different studies.
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error bars. Non-overlap of error bars indicates discrimina-
tion on that axis. Inspection of Fig. 4 suggests, perhaps, that
there is better separation of treatment means with longer
study duration and there seems to be less overlap (i.e.
greater separation between EBA(TTP) error bars than
between EBA(logCFU) error bars). This impression is con-
firmed by the results of ANOVA calculations (Table 2). The
between-treatment F-statistic for EBA(TTP) is considerably
greater than the corresponding statistic for EBA(logCFU)
and the difference is increasing with treatment duration. This
means that the ratio of variability between groups and vari-
ability within groups is better with TTP than with logCFU
and hence TTP discriminates better between EBA group
means than logCFU.
Discussion and Conclusion
This study analysed a very large sample of paired logCFU
and TTP measurements derived from consecutive EBA
FIG. 3. Treatment group logCFU and TTP over time. Twenty-two treatment groups are shown. Each pair of graphs shows EBA(logCFU) on the
left and EBA(TTP) on the right. The x-axis is scaled with 1 logCFU or with 50 h per tick mark, respectively, and the y-axis 2 days per tick mark.
Fourteen-day groups are shown in the first and second columns and 7-day groups in the third column. Bilinear regression lines of logCFU and
TTP on days are shown.
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studies, which included 16 experimental and six positive con-
trol arms. Apart from its size, the consistency of the method
employed is the main strength of this report. All 250 sub-
jects were recruited at a single urban centre, and all samples
were analysed at the same laboratory. LogCFU and TTP
measurements were highly correlated and showed similar
technical and within-subject variation. Rank correlation of
mean EBA and one-way ANOVA allowed the conclusion that
for EBA studies of up to 14 days duration, activity measured
by TTP in liquid media is a valid, if not better, alternative to
activity measured by logCFU counted on solid media. The
high degree of standardization and the superior technical
accessibility could make TTP the preferred endpoint for clini-
cal trials with antituberculosis agents in the future.
Liquid media have better sensitivity for growing mycobac-
teria from sputum than solid media. In treatment studies, this
means that TTP will remain measurable for a longer period
when sputum bacillary loads become low. This is not likely
to be a significant advantage for 2-week EBA studies as long
as experimental treatments are not considerably more effec-
tive than the current standard antituberculosis treatment.
For a typical 8-week phase IIB study, however, TTP in liquid
media could reduce the number of subjects with negative
cultures at 8 weeks (i.e. measurements below detection
level). Assuming that the error variation of TTP in liquid
media remains similar to that of colonies counted on solid
media up to 8 weeks, TTP could substantially increase the
number of data points available for analysis in 8-week treat-
ment trials, a duration of study that has been proposed to
be sufficient to give an indication of sterilizing activity of regi-
mens [18]. As a potential drawback, the greater sensitivity of
liquid media could lead to more missing values due to con-
tamination. This problem was not evident in the present
dataset, but when sputum quality becomes poorer with
increasing study duration contamination rates could increase,
which could make the interpretation of serial TTP measure-
ments difficult.
An interesting note is the non-linear trend of the relation-
ship of TTP and logCFU observed in Fig. 1. From visual
inspection it is plausible that an inherent threshold in the
MGIT liquid culture system prevented TTP decreasing further
when the number of inoculated mycobacteria should have
allowed a lower TTP value. A possible reason for this obser-
vation is a bacterial lag phase induced by the sodium hydrox-
ide-based decontamination procedure before for MGIT
inoculation, which could delay the onset of metabolic activity
independent of the actual number of bacteria inoculated. The
affected area of the curve represents sputa with the highest
bacterial loads, which are the basis of most individual EBA
day 0–2 measurements. This can at least partly explain the




Mean group EBA ranks
(Spearman)
One-way ANOVA
r p r p F (CFU), p F (TTP), p
0–2 20 0.898 <0.001 0.472 0.036 1.87, 0.019 6.58, <0.001
0–7 22 0.898 <0.001 0.910 <0.001 4.58, <0.001 7.77, <0.001
0–14 15 0.919 <0.001 0.818 <0.001 3.56, <0.001 8.71, <0.001
FIG. 4. Discrimination of group EBAs by logCFU and TTP. Treatment means and variation of EBA(logCFU) and EBA(TTP) in hours are calcu-
lated and plotted against each other. The error bars are shown with ±1.4 · SE limits, which are approximate 84% confidence limits. This has
been calculated so that non-overlap of two of these intervals indicates a significant difference at the 95% level. Overlap or non-overlap of these
error bars thus indicates how EBA(logCFU) and EBA(TTP) discriminate between treatment means for EBA day 0–2 (left), EBA day 0–7 (middle),
and EBA day 0–14 (right).
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relatively poorer correlation of TTP and logCFU for EBA day
0–2. A potential solution for this problem is inoculation of a
diluted sample for TTP, which would increase all TTP values
and would allow TTP to spread over a wider range. As a
disadvantage, diluted cultures might remain negative when the
bacterial load becomes very low. This problem awaits resolu-
tion by performing comparative studies with TTP measure-
ments derived from more than one dilution.
In conclusion, we demonstrated that TTP is an adequate
and reliable alternative measurement for EBA studies of up
to 14 days duration. This can have immediate consequences
for site development, cost and speed of clinical antitubercu-
losis drug evaluation.
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